 Nabanita Mukherjee
Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 9 | 2024 | 808 | 3.220 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 7 | 2025 | 245 | 2.160 |
Why?
| | Antineoplastic Agents | 8 | 2025 | 2195 | 1.960 |
Why?
| | Neoplastic Stem Cells | 5 | 2021 | 414 | 1.910 |
Why?
| | Sulfonamides | 6 | 2025 | 582 | 1.450 |
Why?
| | Skin Neoplasms | 4 | 2024 | 869 | 1.430 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 3 | 2024 | 41 | 1.370 |
Why?
| | Nitrophenols | 3 | 2017 | 32 | 1.080 |
Why?
| | Biphenyl Compounds | 3 | 2017 | 70 | 1.040 |
Why?
| | Apoptosis | 6 | 2025 | 2519 | 0.890 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2024 | 72 | 0.770 |
Why?
| | GTP Phosphohydrolases | 2 | 2018 | 96 | 0.670 |
Why?
| | Spheroids, Cellular | 1 | 2021 | 79 | 0.630 |
Why?
| | Aniline Compounds | 1 | 2020 | 120 | 0.600 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 376 | 0.550 |
Why?
| | Molecular Targeted Therapy | 2 | 2025 | 432 | 0.540 |
Why?
| | Microtubule-Associated Proteins | 1 | 2018 | 202 | 0.520 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 1058 | 0.490 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 262 | 0.480 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 626 | 0.450 |
Why?
| | Fenretinide | 1 | 2014 | 4 | 0.440 |
Why?
| | Oligopeptides | 1 | 2016 | 266 | 0.440 |
Why?
| | Peptide Fragments | 1 | 2018 | 702 | 0.430 |
Why?
| | Cell Line, Tumor | 6 | 2021 | 3615 | 0.410 |
Why?
| | Drug Synergism | 3 | 2017 | 370 | 0.340 |
Why?
| | Melanocytes | 2 | 2024 | 66 | 0.330 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 942 | 0.330 |
Why?
| | Genomics | 2 | 2026 | 832 | 0.320 |
Why?
| | Cell Survival | 3 | 2021 | 1136 | 0.320 |
Why?
| | Piperazines | 3 | 2017 | 395 | 0.300 |
Why?
| | Mice | 6 | 2024 | 18423 | 0.280 |
Why?
| | Animals | 8 | 2026 | 38080 | 0.260 |
Why?
| | Cell Self Renewal | 2 | 2017 | 55 | 0.250 |
Why?
| | Mice, Nude | 2 | 2020 | 710 | 0.250 |
Why?
| | Receptors, Histamine | 1 | 2026 | 3 | 0.250 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2025 | 22 | 0.240 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2025 | 12 | 0.240 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2025 | 60 | 0.230 |
Why?
| | Withanolides | 1 | 2025 | 3 | 0.230 |
Why?
| | Thalidomide | 1 | 2025 | 44 | 0.230 |
Why?
| | Translocation, Genetic | 1 | 2025 | 109 | 0.230 |
Why?
| | Silver | 1 | 2025 | 38 | 0.220 |
Why?
| | Metal Nanoparticles | 1 | 2025 | 85 | 0.210 |
Why?
| | Hair Color | 1 | 2024 | 15 | 0.210 |
Why?
| | Mammals | 1 | 2026 | 291 | 0.210 |
Why?
| | Hyperpigmentation | 1 | 2024 | 27 | 0.210 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 2 | 2025 | 266 | 0.200 |
Why?
| | Dexamethasone | 1 | 2025 | 378 | 0.200 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2021 | 879 | 0.190 |
Why?
| | Humans | 16 | 2026 | 143878 | 0.190 |
Why?
| | Multiple Myeloma | 1 | 2025 | 289 | 0.180 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 17 | 0.180 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 78 | 0.170 |
Why?
| | Escherichia coli | 1 | 2025 | 834 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2016 | 1104 | 0.150 |
Why?
| | Dynamins | 1 | 2018 | 38 | 0.140 |
Why?
| | Mutation | 3 | 2021 | 4061 | 0.140 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 188 | 0.130 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2017 | 38 | 0.130 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 928 | 0.130 |
Why?
| | Gene Knockout Techniques | 1 | 2017 | 117 | 0.130 |
Why?
| | Neurofibromin 1 | 1 | 2016 | 25 | 0.130 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2016 | 78 | 0.120 |
Why?
| | Pyrroles | 1 | 2017 | 211 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 1832 | 0.120 |
Why?
| | Retinoids | 1 | 2014 | 34 | 0.110 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2016 | 230 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1911 | 0.110 |
Why?
| | Complementary Therapies | 1 | 2015 | 92 | 0.100 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2014 | 100 | 0.100 |
Why?
| | Survival Analysis | 1 | 2015 | 1332 | 0.090 |
Why?
| | Evolution, Molecular | 2 | 2026 | 507 | 0.090 |
Why?
| | Amino Acid Sequence | 2 | 2026 | 2167 | 0.090 |
Why?
| | Membrane Proteins | 1 | 2016 | 1177 | 0.080 |
Why?
| | Neoplasms | 1 | 2025 | 2812 | 0.080 |
Why?
| | Female | 5 | 2025 | 77456 | 0.070 |
Why?
| | Biomarkers, Tumor | 1 | 2014 | 1286 | 0.070 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4544 | 0.060 |
Why?
| | Prognosis | 1 | 2015 | 4164 | 0.060 |
Why?
| | Withania | 1 | 2025 | 6 | 0.060 |
Why?
| | Risk Assessment | 1 | 2015 | 3585 | 0.060 |
Why?
| | Microbial Sensitivity Tests | 1 | 2025 | 372 | 0.050 |
Why?
| | Plant Extracts | 1 | 2025 | 212 | 0.050 |
Why?
| | Pedigree | 1 | 2024 | 513 | 0.050 |
Why?
| | Cell Lineage | 1 | 2024 | 370 | 0.050 |
Why?
| | Tumor Suppressor Proteins | 1 | 2024 | 330 | 0.040 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2021 | 57 | 0.040 |
Why?
| | Phylogeny | 1 | 2026 | 1008 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2015 | 11390 | 0.040 |
Why?
| | Male | 3 | 2025 | 71702 | 0.030 |
Why?
| | Phenotype | 1 | 2024 | 3210 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2025 | 8077 | 0.020 |
Why?
| | Adult | 2 | 2025 | 40116 | 0.020 |
Why?
| | Aged | 1 | 2025 | 25377 | 0.010 |
Why?
| | Middle Aged | 1 | 2025 | 35429 | 0.010 |
Why?
|
|
Mukherjee's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|